Publication date: Jun 22, 2025
), indicating that 1 additional death could be avoided for every 16 patients treated with TNF- inhibitors compared to standard of care. Outcomes assessed included mortality, invasive mechanical ventilation, and C-reactive protein (CRP) levels. Photo Credit: iStock. com/TirachardTNF- inhibitors may reduce mortality and inflammation in moderate-to-severe COVID-19 cases. No significant reduction in the need for invasive mechanical ventilation was observed (OR 0. 95 [95% CI 0. 461. 94]; P= 0. 822). The number needed to treat for mortality was calculated to be 16 (95% CI 9. 0-inf. Data from studies published up to August 12, 2024, were analyzed.
| Concepts | Keywords |
|---|---|
| Biomedcentral | Care |
| Necrosis | Com |
| Vaccination | Covid |
| Critical | |
| Effectiveness | |
| Inhibitors | |
| Moderate | |
| Mortality | |
| Needed | |
| Published | |
| Safety | |
| Severe | |
| Significant | |
| Tnf | |
| Treatment |
Semantics
| Type | Source | Name |
|---|---|---|
| disease | MESH | death |
| pathway | REACTOME | SARS-CoV-2 Infection |
| disease | MESH | inflammation |
| drug | DRUGBANK | Coenzyme M |
| disease | MESH | COVID-19 |
| disease | IDO | role |
| disease | MESH | cytokine storm |
Original Article
(Visited 2 times, 1 visits today)